Shanghai Runda Medical Technology Co EV/OCF
The EV/OCF (Enterprise Value to Operating Cash Flow) of Shanghai Runda Medical Technology Co (603108.SS) as of Aug 2, 2026 is 24.38. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 21.66 — a change of 12.58% (higher).
Get this data via API
Financial Data API
EV/OCF
24.38
YoY
12.58%
Last updated:
EV/OCF (Enterprise Value to Operating Cash Flow) of Shanghai Runda Medical Technology Co is 2026 24.38 . EV/OCF (Enterprise Value to Operating Cash Flow) of Shanghai Runda Medical Technology Co was 2025 21.66 . It decreases by 12.58% higher compared to the previous year.
Access this data via the Eulerpool API
Shanghai Runda Medical Technology Co Stock analysis
What does Shanghai Runda Medical Technology Co do? Shanghai Runda Medical Technology Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Shanghai Runda Medical Technology Co stock
EV/OCF (Enterprise Value to Operating Cash Flow) of Shanghai Runda Medical Technology Co is 24.38 in 2026.
Access this data via the Eulerpool API
Valuation — Shanghai Runda Medical Technology Co
All Key Metrics — Shanghai Runda Medical Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth